1. |
Søndergaard L, Saraste A, Christersson C, et al. The year in cardiology 2017: valvular heart disease. Eur Heart J, 2018, 39(8): 650-657.
|
2. |
Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation, 2012, 126(13): 1630-1639.
|
3. |
Ayoub K, Nairooz R, Almomani A, et al. Perioperative heparin bridging in atrial fibrillation patients requiring temporary interruption of anticoagulation: evidence from Meta-analysis. J Stroke Cerebrovasc Dis, 2016, 25(9): 2215-2221.
|
4. |
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 63(22): 2438-2488.
|
5. |
Mittmann N, Henry B, Murshed S, et al. Does warfarin use impact hospital length of stay? A retrospective study looking at patients treated for atrial fibrillation. Hosp Top, 2013, 91(1): 20-24.
|
6. |
Bola S, Marsh R, Braggins S, et al. Does the continuation of warfarin change management outcomes in epistaxis patients? J Laryngol Otol, 2016, 130(3): 256-260.
|
7. |
Ahmed I, Gertner E, Nelson WB, et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm, 2010, 7(6): 745-749.
|
8. |
Feng L, Li Y, Li J, et al. Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices: a meta-analysis. Thromb Haemost, 2012, 108(6): 1124-1131.
|
9. |
Tyagi G, Pai SM, Pai RG. Cardiac rhythm device surgery with uninterrupted oral anticoagulation. Future Cardiol, 2013, 9(6): 763-766.
|
10. |
Westerman ME, Scales JA, Sharma V, et al. The effect of anticoagulation on bleeding-related complications following ureteroscopy. Urology, 2017, 100: 45-52.
|
11. |
吴慧婷, 钱成, 丁进叶, 等. 持续口服华法林和肝素桥接对心房颤动消融术后并发症影响的 Meta 分析. 中国循证心血管医学杂志, 2016, 8(5): 520-523.
|
12. |
Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med, 2015, 16(1): 11-17.
|
13. |
Saad EB, Costa IP, Costa RE, et al. Safety of ablation for atrial fibrillation with therapeutic INR: comparison with transition to low-molecular-weight heparin. Arq Bras Cardiol, 2011, 97(4): 289-296.
|
14. |
Eijgenraam P, ten Cate H, ten Cate-Hoek AJ. Practice of bridging anticoagulation: guideline adherence and risk factors for bleeding. Neth J Med, 2014, 72(3): 157-164.
|
15. |
Rechenmacher SJ, Fang JC. Bridging anticoagulation: primum non nocere. J Am Coll Cardiol, 2015, 66(12): 1392-1403.
|
16. |
Airaksinen KE, Korkeila P, Lund J, et al. Safety of pacemaker and implantable cardioverter-defibrillator implantation during uninterrupted warfarin treatment--the FinPAC study. Int J Cardiol, 2013, 168(4): 3679-3682.
|